Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma
Cells · 14.02.2023 · 12 (4) · 612
DOI: 10.3390/cells12040612 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 14.02.2023. Verfasst von Katsuki Miyazaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Curcumin, Liver Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Cancer Institute and the National Institutes of Health, Research Program on Hepatitis from the Japanese foundation for multidisciplinary cancer treatment.
Abstract (Originalsprache)
Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
- Department of Surgery, Tokushima University, Tokushima 779-1510, Japan.
ORCID-Profile: Katsuki Miyazaki, Caiming Xu, Yuma Wada, Ajay Goel
Förderung
- NIH HHS
- National Cancer Institute and the National Institutes of Health
- Research Program on Hepatitis from the Japanese foundation for multidisciplinary cancer treatment
- Japan Agency for Medical Research and Development (AMED)
- Grant-in-Aid for Scientific Research
Zitieren
APA
Miyazaki, K., Morine, Y., Xu, C., Nakasu, C., Wada, Y., Teraoku, H., Yamada, S., Saito, Y., Ikemoto, T., Shimada, M., & Goel, A. (2023). Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells, 12(4), 612. https://doi.org/10.3390/cells12040612
Vancouver
Miyazaki K, Morine Y, Xu C, Nakasu C, Wada Y, Teraoku H, et al. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells. 2023;12(4):612. doi:10.3390/cells12040612
BibTeX
@article{Miyazaki2023,
author = {Miyazaki, Katsuki and Morine, Yuji and Xu, Caiming and Nakasu, Chiharu and Wada, Yuma and Teraoku, Hiroki and Yamada, Shinichiro and Saito, Yu and Ikemoto, Tetsuya and Shimada, Mitsuo and Goel, Ajay},
title = {Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma},
journal = {Cells},
year = {2023},
volume = {12},
number = {4},
pages = {612},
doi = {10.3390/cells12040612}
}
EUVIMED